I serve as medical director of oncology at JamesCare at University Hospital East and as an assistant professor in the Department of Internal Medicine. There’s a tremendous amount of camaraderie and mutual respect here, and I’m honored to be a part of this world-class organization.
At The James, we value a multidisciplinary approach to care. I enjoy collaborating with colleagues, patients, patients’ family members and outside healthcare providers to come up with individualized treatment plans. We are not reluctant to utilize innovative, cutting-edge approaches and therapies.
Finding ways to improve cancer treatment is another important part of my career. I’m a member of several clinical trial cooperative groups, including the Leukemia Group B (CALGB), the Cancer Trials Support Unit (CTSU), the National Surgical Adjuvant Breast and Bowel Project (NSABP) as well as the Radiation Therapy Oncology Group (RTOG).
Ohio State University College of Medicine
Specialties and conditions I treat
- Medical Oncology
- Blood Cancers
- Hematologic Diseases
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Neuroendocrine Tumors
- Lung Cancers
- Digestive System Cancers
- Second Primary Cancers
- Unknown Primary Tumor
- Paraneoplastic Syndromes
Locations where I practice
JamesCare at University Hospital East
More about my work
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Hematology)
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Rupert has reported no financial relationships with medical device, research and/or drug companies.